Comparison between genotype and phenotype identifies a high-risk population carrying BRCAI mutations

Genes Chromosomes and Cancer

Volumn 27, Issue 2, 2000, Pages 130-135

  Cortesi, Laura ^a   Turchetti, Daniela ^a   Bertoni, Chiara ^a   Bellei, Roberta ^a   Mangone, Lucia ^a   Vinceti, Marco ^a   Federico, Massimo ^a   Silingardi, Vittorio ^a   Ferrari, Sergio ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MUTATION RATE; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL;

ADULT; AGE OF ONSET; AGED; BASE SEQUENCE; BREAST NEOPLASMS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FAMILY HEALTH; FEMALE; GENE FREQUENCY; GENES, BRCA1; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; MUTATION; MUTATION, MISSENSE; PEDIGREE; PHENOTYPE; POINT MUTATION; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 0033987956     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2264(200002)27:2<130::AID-GCC3>3.0.CO;2-U     Document Type: Article

References (38)

1. Abbondanza C, De Falco A, Nigro V, Medici N, Armetta I, Molinari AM, Moncharmont B, Puca GA. 1993. Characterization and epitope mapping of a new panel of monoclonal antibodies to estradiol receptor. Steroids 58:4-12.
2. Armes JE, Egan AJM, Southey MC, Dite GS, McCredie MRE, Giles GG, Hopper JL, Venter DJ. 1998. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations. Cancer 83:2335-2345.
3. ASCO. 1996. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility. J Clin Oncol 14:1730-1736.
4. Birch JM. 1990. The Li-Fraumeni cancer family syndrome. J Pathol 161:1-2.
5. Brown DC, Gatter KC. 1990. Monoclonal antibody Ki-67: its use in histopathology. Histopathology 17:489-503.
6. De Benedetti VM, Radice P, Mondini P, Spatti O, Conti A, Illeni MT, Caligo MA, Cipollini G, Bevilacqua G, Pilotti S, Pierotti MA. 1996. Screening for mutations in exon 11 of the BRCA1 gene in 70 Italian breast and ovarian cancer patients by protein truncation test. Oncogcne 13:1353-1357.
7. Eisinger F, Stoppa-Lyonnet D, Longy M, Kerangueven F, Noguchi T, Bailly C, Vincent-Salomon A, Jacquemier J, Birnbaum D, Sobol H. 1996. Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res 56:471-474.
8. Elston CW, Ellis IO. 1991. Pathological prognostic factors in BC: the value of histological grade in BC: experience from a large study with long term follow-up. Histopathology 19:403-410.
9. Federico M, Maiorana A, Mangone L, Turchetti D, Canossi B, Cortesi L, Romagnoli R, Silingardi V. 1999. Identification of families with hereditary breast and ovarian cancer for clinical and mammographic surveillance: the Modena study group proposal. Breast Cancer Res Treat 55:213-221.
10. Friedman LS, Ostermeyer EA, Szabo CI, Dowd P, Lynch ED, Rowell SE, King MC. 1995. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet 8:399-404.
11. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC. 1990. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250:1684-1689.
12. Hanahan D. 1983. Studies on transformation of Escherichia coli with plasmids. J Mol Biol 166:557-580.
13. Hogervorst FB, Cornelis RS, Bout M, van-Vliet M, Oosterwijk JC, Olmer R, Bakker B, Klijn JG, Vasen HF, Meijers-Heijboer H, Menko FH, Cornelisse CJ, den Dunnen JT, Devilee P, van Ommen GJB. 1995. Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet 10:208-212.
14. Hosmer DW, Lemeshow S. 1989. Applied Logistic Regression. New York: John Wiley & Sons.
15. Johannsson O, Ostermeyer EA, Hakansson S, Friedman LS, Johansson U, Sellberg G, Brondum-Nielsen K, Sele V, Olsson H, King MC, Borg A. 1996. Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden. Am J Hum Genet 58:441-450.
16. Li FP, Garber JE, Friend FH, Strong LC, Patenaude AF, Juengst ET, Reilly PR, Correa P, Fraumeni JF Jr. 1992. Recommendations of predictive testing for germ-line p53 mutations among cancer-prone individuals. J Natl Cancer Inst 84:1156-1160.
17. Loman N, Johannsson O, Bendahl PO, Borg A, Ferno M, Olsson H. 1998. Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer 83:310-319.
18. Lynch HT, Guirgis HA, Albert S, Brennan M, Lynch J, Kraft C, Pocekay D, Vaughns C, Kaplan A. 1974. Familial association of carcinoma of the breast and ovary. Surg Gynccol Obstet 138:717-724.
19. Lynch HT, Watson P, Conway T, Fitzsimmons ML, Lynch J. 1988. Breast cancer family history as a risk factor for early onset breast cancer. Breast Cancer Res Treat 11:263-267.
20. Lynch HT, Watson P, Conway TA, Lynch JF. 1992. Natural history and age at onset of hereditary breast cancer. Cancer 69:1404-1407.
21. Lynch HT, Lynch J, Conway T, Watson P, Feunteun J, Lenoir G, Narod S, Fitgibbons R Jr. 1994. Hereditary breast cancer and family cancer syndromes. World J Surg 18:21-31.
22. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA. 1990. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 250:1233-1238.
23. Marcus JN, Watson P, Page DL, Narod SA, Lenoir GM, Tonin P, Linder-Stephenson L, Salerno G, Conway TA, Lynch HT. 1996. Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 77:697-709.
24. Montagna M, Santacatterina M, Corneo B, Menin C, Serova O, Lenoir GM, Chieco-Bianchi L, D'Andrea E. 1996. Identification of seven new BRCA1 germline mutations in Italian breast and breast/ovarian cancer families. Cancer Res 56:5466-5469.
25. Monteiro AN, August A, Hanafusa H. 1996. Evidence for a transcriptional activation function of BRCA1 C-terminal region. Proc Natl Acad Sci USA 93:13595-13599.
26. Morrell D, Cromartie E, Swift M. 1986. Mortality and cancer incidence in 263 patients with AT. J Natl Cancer Inst 77:89-92.
27. Muller-Holzner E, Zeimet AG, Daxenbichler G, Marth C, Muller LC, Dapunt O. 1993. Progesterone receptors in routinely paraffin-embedded primary breast carcinomas and lymph node metastases. Breast Cancer Res Treat 25:47-55.
28. Newman B, Austin MA, Lee M, King MC. 1988. Inheritance of human breast cancer: evidence for autosomal dominant transmission in high risk families. Proc Natl Acad Sci USA 85:3044-3048.
29. Olopade IO. 1997. Genetic Testing, Guidelines, Ethics: When to Test and What to Do With the Results. Philadelphia, PA: ASCO Educational Book, p 58-62.
30. Olsen JH, Seersholm N, Boice JD Jr, Kruger-Kjaer S, Franmeni-JF Jr. 1999. Cancer risk in close relatives of women with early-onset breast cancer: a population-based incidence study. Br J Cancer 79:673-679.
31. Padberg GW, Schot JD, Vielvoye GJ, Bots GT, de Beer FC. 1991. Lhermitte-Duclos disease and Cowden disease: a single phakomatosis. Ann Neurol 29:517-523.
32. Rebbeck TR, Kantoff PW, Krithivas K, Neuhansen S, Blackwood MA, Godwin AK, Daly MB, Narod SA, Garber JE, Lynch HT, Weber BL, Brown M. 1999. Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am J Hum Genet 64:1371-1377.
33. Risinger JI, Barrctt JC, Watson P, Lynch HT, Boyd J. 1996. Molecular genetic evidence of the occurrence of breast cancer as an integral tumor in patients with the hereditary nonpolyposis colorectal carcinoma syndrome. Cancer 77:1836-1843.
34. Sattin RW, Rubin GL, Webster LA, Huezo CM, Wingo PA, Ory HW, Layde PM. 1985. Family history and the risk of breast cancer. JAMA 253:1908-1913.
35. Savitsky K, Sfez S, Tagle DA, Ziv Y, Sartiel A, Collins FS, Shiloh Y, Rotman G. 1995. The complete sequence of the coding region of ATM gene reveals similarity to cell cycle regulators in different species. Hum Mol Genet 4:2025-2032.
36. Shattuck-Eidens D, Oliphant A, McClure M, McBride C, Gupte J, Rubano T, Pruss D, Tavtigian SV, Teng DH, Adey N, Staebell M, Gumpper K, Lundstrom R, Hulick M, Kelly M, Holmen J, Lingenfelter B, Manley S, Fujimura F, Luce M, Ward B, Cannon-Albright L, Steele L, Offit K, Gilewski T, Norton L, Brown K, Schulz C, Hampel H, Schluger A, Giulotto E, Zoli W, Ravaioli A, Nevanlinna H, Pyrhonen S, Rowley P, Loader S, Osborne MP, Daly M, Tepler I, Weinstein PL, Scalia JL, Michaelson R, Scott RJ, Radice P, Pierotti MA, Garber JE, Isaacs C, Peshkin B, Lippman ME, Dosik MH, Caligo MA, Greenstein RM, Pilarski R, Weber B, Burgemeister R, Frank TS, Skolnick MH, Thomas A. 1997. BRCA1 sequence analysis in women at high risk for susceptibility mutations: risk factor analysis and implications for genetic testing. JAMA 278:1242-1250.
37. Wu LC, Wang ZW, Tsan JT, Spillman MA, Phung A, Xu XL, Yang MC, Hwang LY, Bowcock AM, Baer R. 1996. Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat Genet 14:430-440.
38. Wooster R, Neuhausen S, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D, Fields P, Marshall G, Narod S, Lenoir GM, Lynch H, Feunteun J, Devilee P, Cornelisse CJ, Menko FH, Daly PA, Ormiston W, McManus R, Pye C, Lewis CM, Cannon-Albright LA, Peto J, Ponder BAJ, Skolnick MH, Easton DF, Goldgar DE, Stratton MR. 1994. Localization of a breast cancer susceptibility gene, RRCA2, to chromosome 13q12-13. Science 265:2088-2090.